Among 9280 patients with confirmed SARS-CoV-2 infection from 68 hospitals of the Veneto Region (North-Eastern Italy), those affected by prostate cancer and not receiving androgen-deprivation therapy were significantly more susceptible to COVID-19 (OR = 4.05; 95%CI: 1.55–10.59) than those receiving androgen deprivation (which decreases TMPRSS2 expression) [58]. This evidence concerns the gene TMPRSS2 and prostate cancer.